KatsanosKSpiliopoulosSKitrouP, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: A systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.
2.
TepeGSchnorrBAlbrechtT, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8:102–108.
3.
DakeMDAnselGMJaffMR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.
4.
SalisburyACLiHVilainKR, et al. Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: Results from the IN.PACT SFA II trial. JACC Cardiovasc Interv. 2016;9:2343–2352.
5.
CaraduCLakhlifiEColacchioEC, et al. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J Vasc Surg. 2019;70:981–995.e10.
6.
AboyansVRiccoJBBartelinkMEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: The European Stroke Organization (ESO), the task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.
7.
FeldmanDNArmstrongEJAronowHD, et al. SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions. Catheter Cardiovasc Interv. 2018;92:124–140.
8.
HoldenAVarcoeRLJaffMR, et al. Paclitaxel and mortality: the dose argument is critical. J Endovasc Ther. 2019;26:467–470.
9.
KatsukiTTakaharaMSogaY, et al. Mortality risk following application of a paclitaxel-coated stent in femoropopliteal lesions. J Endovasc Ther. 2019;26:563–569.
10.
SchneiderPALairdJRDorosG, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol. 2019;73:2550–2563.
11.
TakaharaMIidaOSogaY, et al. Mortality risk of femoropopliteal paclitaxel-coated devices remains inconclusive. Cardiovasc Interv Ther. 2019;34:194–195.
12.
SecemskyEAKundiHWeinbergI, et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019;4:332–340.
13.
FanelliFCorteseBZellerT. Use of paclitaxel-eluting technologies in the femoropopliteal segment under scrutiny over possible link to late all-cause mortality: time to panic or an opportunity to resurge? [Editorial]J Endovasc Ther. 2019;26:41–43.
14.
ZellerTNooryEBeschornerU, et al. Outstanding effectiveness of paclitaxel-based technologies for the treatment of femoropopliteal artery occlusive disease on the potential expense of increased late all-cause mortality? No reason to panic. Vasa. 2019;48:109–111.
15.
RowinskyEKDonehowerRC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004–1014.
AliRMAbdul KaderMWan AhmadWA, et al. Treatment of coronary drug-eluting stent restenosis by a sirolimus- or paclitaxel-coated balloon. JACC Cardiovasc Interv. 2019;12:558–566.
19.
LemosPAFarooqVTakimuraCK, et al. Emerging technologies: Polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention. 2013;9:148–156.
20.
DaniSShahDSojitraP, et al. A novel nanocarrier sirolimus-coated balloon for coronary interventions: 12-month data from the Nanolute registry. Cardiovasc Revasc Med. 2019;20:235–240.
ZellerT. First report of the SELUTION trial: 6-month outcomes of a novel sirolimus coated DCB technology evaluated in the SFA. Paper presented at: LINC; January 31, 2018; Leipzig, Germany.
24.
CorteseBSilva OrregoPAgostoniP, et al. Effect of drug-coated balloons in native coronary artery disease left with a dissection. JACC Cardiovasc Interv. 2015;8:2003–2009.
25.
DiamantopoulosAGuptaYZayedH, et al. Paclitaxel-coated balloons and aneurysm formation in peripheral vessels. J Vasc Surg. 2015;62(5):1320–1322.
